Playback speed
10 seconds
Tumor Mutational Burden in SCLC: A Valuable Immunotherapy Biomarker?
By
Beacon Medical Interchange
FEATURING
Jack West
By
Beacon Medical Interchange
FEATURING
Jack West
514 views
November 2, 2018
Dr. Jack West reviews new findings highlighting the utility of using the biomarker tumor mutation ...
read more ↘ burden (TMB) to predict which patients with small cell lung cancer (SCLC) will benefit from nivolumab or the combination of nivolumab with ipilimumab.
↖ read less
read more ↘ burden (TMB) to predict which patients with small cell lung cancer (SCLC) will benefit from nivolumab or the combination of nivolumab with ipilimumab.
↖ read less
Comments 0
Login to view comments.
Click here to Login
Lung